Last reviewed · How we verify
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa (Landscape)
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
Details
| Lead sponsor | Beacon Therapeutics |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 10 |
| Start date | Wed Sep 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Dec 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- X-Linked Retinitis Pigmentosa (XLRP)
Interventions
- Adeno-associated virus vector expressing a human RPGR gene
Countries
United States